Critical limb ischemia

被引:51
作者
Schanzer A. [2 ]
Conte M.S. [1 ]
机构
[1] Division of Vascular and Endovascular Surgery, Heart and Vascular Center, University of California, San Francisco, San Francisco, CA 94143
[2] University of Massachusetts, Memorial Medical Center, Worcester, MA 01655
关键词
Peripheral Arterial Disease; Critical Limb Ischemia; Endovascular Therapy; Intermittent Pneumatic Compression; Critical Limb Ischemia Patient;
D O I
10.1007/s11936-010-0076-7
中图分类号
学科分类号
摘要
Critical limb ischemia (CLI), defined as chronic ischemic rest pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease, is the most advanced form of peripheral arterial disease. Traditionally, open surgical bypass was the only effective treatment strategy for limb revascularization in this patient population. However, during the past decade, the introduction and evolution of endovascular procedures have significantly increased treatment options. In a certain subset of patients for whom either surgical or endovascular revascularization may not be appropriate, primary amputation remains a third treatment option. Definitive high-level evidence on which to base treatment decisions, with an emphasis on clinical and cost effectiveness, is still lacking. Treatment decisions in CLI are individualized, based on life expectancy, functional status, anatomy of the arterial occlusive disease, and surgical risk. For patients with aortoiliac disease, endovascular therapy has become first-line therapy for all but the most severe patterns of occlusion, and aortofemoral bypass surgery is a highly effective and durable treatment for the latter group. For infrainguinal disease, the available data suggest that surgical bypass with vein is the preferred therapy for CLI patients likely to survive 2 years or more, and for those with long segment occlusions or severe infrapopliteal disease who have an acceptable surgical risk. Endovascular therapy may be preferred in patients with reduced life expectancy, those who lack usable vein for bypass or who are at elevated risk for operation, and those with less severe arterial occlusions. Patients with unreconstructable disease, extensive necrosis involving weight-bearing areas, nonambulatory status, or other severe comorbidities may be considered for primary amputation or palliative measures. © The Author(s) 2010.
引用
收藏
页码:214 / 229
页数:15
相关论文
共 79 条
[11]  
DeRubertis B.G., Faries P.L., McKinsey J.F., Et al., Shifting paradigms in the treatment of lower extremity vascular disease: A report of 1000 percutaneous interventions, Ann Surg, 246, pp. 415-422, (2007)
[12]  
Goodney P.P., Beck A.W., Nagle J., Et al., National trends in lower extremity bypass surgery, endovascular interventions, and major amputations, J Vasc Surg, 50, pp. 54-60, (2009)
[13]  
Hirsch A.T., Haskal Z.J., Hertzer N.R., Et al., American Association for Vascular Surgery
[14]  
Society for Vascular Surgery
[15]  
Society for Cardiovascular Angiography and Interventions
[16]  
Society for Vascular Medicine and Biology
[17]  
Society of Interventional Radiology
[18]  
ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease, Circulation, 113, (2006)
[19]  
Price J.F., Mowbray P.I., Lee A.J., Et al., Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh artery study, Eur Heart J, 20, pp. 344-353, (1999)
[20]  
Brass E.P., Anthony R., Dormandy J., Et al., Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia, J Vasc Surg, 43, pp. 752-759, (2006)